Amphastar Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Amphastar Pharmaceuticals (Rancho Cucamonga, CA): 5 reconciled FDA prescription therapies (0.0% 2025 to 2030 cliff risk), $121.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Rancho Cucamonga, CA |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $121.5M |
| 2024 Medicare Part D Spend | $40.5M |
| 2024 Medicaid Spend | $81.0M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |